Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.

Bernard Douglas MayburyLisa Jane JamesNeil PhillipsIndrani VenkatadasariIman QureshiJames William Elliot RileyGeorgina TalbotShivir MoosaiHannah Victoria GilesNicola ChaddertonJames DowdsPallav RakeshHenry CroslandAidan HaslamSarah LaneMonica Vega GonzalezDavid DaviesGeorge CherianAmir ShenoudaPraveen Kumar Kaudlay SathyanarayanaJane StarczynskiZbigniew RudzkiSridhar Chaganti

Published in: Blood (2024)

A reciprocal t(3;8) BCL6::MYC fusion is common in large B cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo-double hit cases are not adverse, whereas t(3;8) negative MYC/BCL6 lymphoma has an inferior prognosis relative to other MYC-rearranged LBCL.

Keyphrases

transcription factor
diffuse large b cell lymphoma
emergency department
clinical trial
gene expression
dna methylation
free survival
adverse drug
double blind